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Ib or Not IIb? Toward
Rational Application
f Left Main Stenting*
arry F. Uretsky, MD
ittle Rock, Arkansas
or over 30 years, the elective treatment of significant left
ain (LM) coronary disease has been the province of
oronary artery bypass surgery (CABG). Recently, several
arge registries using either bare-metal stents (BMS) or
rug-eluting stents (DES) and 1 large clinical trial, the
YNTAX (Synergy between Percutaneous Coronary Inter-
ention with Taxus and Cardiac Surgery) trial, have pro-
ided insights into stenting as an acceptable alternative to
ABG (1–4). These studies have demonstrated the relative
afety and efficacy of stenting, similar mortality and myo-
ardial infarction (MI) outcomes with BMS and DES, and
ecreased target vessel revascularization (TVR) with DES
ompared with BMS (4,5).
See page 2544
In this issue of the Journal, Kim et al. (6) address the
uestion from a large “real-world” registry (2) as to whether
he extent of coronary disease as characterized by the
umber of coronary vessels outside the LM with a signifi-
ant (50%) diameter stenosis affects long-term outcomes
4 years) with percutaneous coronary intervention (PCI)
ersus CABG. There was no significant difference in the
ombined end point of death, MI, or stroke in any coronary
rtery disease subgroup, including patients with the greatest
isease burden. These “real-world” results are similar to
hose reported in the SYNTAX randomized trial (1). TVR
as more frequent with PCI in the entire group and in both
he DES and BMS subgroups. Incidence of TVR was
imilar in magnitude to that reported in SYNTAX. How-
ver, unlike SYNTAX, where there was a somewhat lower
ate of major adverse cardiac or cerebrovascular events
death, MI, cerebrovascular accident, TVR) with DES in
elatively less extensive disease (isolated LM or LM plus
Editorials published in the Journal of the American College of Cardiology reflect the
iews of the authors and do not necessarily represent the views of JACC or the
merican College of Cardiology.e
From the Division of Cardiology, University of Arkansas for Medical Sciences,
entral Arkansas Veterans Health System, Little Rock, Arkansas.-vessel disease) and a somewhat higher rate of major
dverse cardiac or cerebrovascular events in more extensive
isease, the rate of major adverse cardiac or cerebrovascular
vents was higher with PCI in all subgroups in this registry.
s noted by Kim et al. (6), this finding may have been
elated in part to the policy of surveillance follow-up
ngiography (performed in 73% of PCI patients vs. 15% of
ABG patients). Routine follow-up angiography has been
reviously shown to increase TVR rates in asymptomatic
ost-PCI patients (7).
The inherent limitation of this study, as in all registry
tudies, relates to selection and other hidden biases. That
eing said, the size of the study, the thoroughness of the
ata analysis, and similarity of results with other data
ncluding the SYNTAX trial provide a measure of confi-
ence in the reliability of the findings.
This study, in combination with other reports, particu-
arly SYNTAX, allows for certain conclusions regarding
utcomes for stenting compared with CABG:
• Major adverse outcomes—death, MI, and stroke—at
intermediate follow-up are similar for both therapies.
Follow-up has been presented through 2 years for
SYNTAX (8), through 4 years in the current study (6),
and as long as 10 years for BMS (9).
In ARTS (Arterial Revascularization Therapies
Study), comparing BMS in multivessel disease (ex-
cluding LM) to CABG, 5-year follow-up showed that
the majority of the adverse events and separation of
curves occurred within the first year, with the curves
flattening out for both therapies through 5 years (10).
Multiple registries of LM stenting of 3 years or longer
including the present one have shown similar results
(2,3,6,9,11). Thus, it seems unlikely that there will be
a major shift in the SYNTAX trial in the relative safety
of these 2 therapies as follow-up time increases.
• Stroke risk may be higher with CABG than PCI,
although the absolute incidence and difference be-
tween therapies are small (1). In the SYNTAX trial,
the stroke rate for LM patients was 2.7% with CABG
and 0.3% for DES (p  0.01). In the present study,
the difference was less impressive both in the entire
cohort (CABG: 1.7%, PCI: 1.1%) as well as in both
the BMS and DES (CABG: 1.8%, DES: 1.5%)
subgroups.
• Repeat TVR risk with DES is higher with PCI (2
times in SYNTAX, almost 5 times in the current
study).
These conclusions do not sustain a New York Heart
ssociation functional class III recommendation that LM
tenting demonstrates a risk greater than benefit ratio
12,13). The American Heart Association/American Col-
ege of Cardiology PCI guideline has recently been updated
o reflect this fact (14). Left main stenting in patients
ligible for CABG has been changed to a class IIb recom-
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IIb or Not IIb? Left Main Stenting June 8, 2010:2553–5endation. Class IIb has been defined as an intervention in
hich the benefit is greater than the risk and “may be
onsidered” in an individual patient but the efficacy and
afety are far from certain and that “additional studies with
road objectives are needed” and “additional registry data
ay be considered.” The update emphasizes caution in the
se of LM stenting because of the severe downside risk
hould complications occur and presents the need to clarify
ome of the unknown aspects to optimize results such as the
se of intravascular ultrasound. It is likely that further
iscussion will ensue as to whether the current knowledge
ase for LM stenting justifies an IIa rather than an IIb
ecommendation. Selection of which patient “may be con-
idered” for LM stenting will certainly be an actively
ebated topic.
To make the best decision for an individual patient,
lfonso (15) has recommended “balanced counseling”
mong physicians and the patient. In this context, it seems
easonable that physicians in a given center should (to use a
egal term) “stipulate” that the preceding 3 conclusions are
rue and need not be argued in deciding how to best treat
he individual patient. The discussion will then focus on the
pproximated surgical versus PCI mortality risk for that
atient; the anticipated completeness of revascularization
ith each technique; patient compliance (particularly for
CI with the need for prolonged dual antiplatelet therapy);
he potential for CABG complications such as stroke, atrial
brillation, wound infection, and such versus the estimated
isk of repeat revascularization with PCI; and other patient-
pecific issues. To illustrate, we might ask what the best
reatment would be for a frail octogenarian with severe
ife-limiting angina and multiple comorbidities. Existing
ata, albeit with their own limitations, suggest that PCI
ay be particularly valuable in this setting (16). On the
ther hand, a 50-year-old otherwise healthy individual with
o comorbidities at low surgical risk may be better served in
erms of minimizing health care utilization by undergoing
ABG. Further clarification of which clinical characteris-
ics may best recommend a patient for either PCI or CABG
ill aid in decision making (15).
As a procedure in evolution, there are many unresolved
uestions related to optimizing outcome. For example, as
oted in the updated guidelines, should intravascular ultra-
ound be routinely used in evaluating results (17)? Should
tenting be confined to ostial and shaft lesions, as suggested
y the guidelines update, or should bifurcation lesions as in
he current study be included? Is increased TVR at bifur-
ations versus shaft/ostial lesions due to anatomical or
echnical factors or both? Should fractional flow reserve be
sed to select appropriate candidates and to optimize results
18)? Should an anatomic score such as the SYNTAX score
e used as a guide to the type of treatment (19)? Should 1
tent or 2 be used routinely for bifurcation lesions? When 2
tents are needed, which technique should be preferred?
ow long should dual antiplatelet therapy be given? These
nd other questions will certainly be addressed in futuretudies. Kim et al. (6) have provided, in their large patient
ohort analysis, reassurance that long-term major adverse
utcomes after LM stenting, both with BMS and DES,
ompare favorably with bypass surgery, thus providing
ncreased confidence to the treating physician who must
valuate which therapy is preferred for the individual
atient.
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ivision of Cardiology, Central Arkansas Veterans Health Sys-
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